Ken Griffin Compugen LTD Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1.56 - $2.1 $12,792 - $17,220	-8,200 Reduced 46.59%	9,400 $17,000
Q2 2024 Aug 14, 2024	BUY	$1.68 - $2.52 $7,056 - $10,584	4,200 Added 31.34%	17,600 $29,000
Q1 2024 May 15, 2024	SELL	$1.75 - $2.95 $32,375 - $54,575	-18,500 Reduced 57.99%	13,400 $34,000
Q4 2023 Feb 14, 2024	BUY	$0.53 - $2.0 $7,579 - $28,600	14,300 Added 81.25%	31,900 $63,000
Q3 2023 Nov 14, 2023	BUY	$0.88 - $1.31 $704 - $1,048	800 Added 4.76%	17,600 $16,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.38 $9,576 - $23,184	16,800 New	16,800 $19,000
Q4 2022 Feb 14, 2023	BUY	$0.58 - $1.2 $6,496 - $13,440	11,200 Added 33.33%	44,800 $32,000
Q3 2022 Nov 14, 2022	BUY	$0.66 - $2.32 $22,176 - $77,952	33,600 New	33,600 $22,000

13.1M

79.2K

12.7K

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $122M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.